Objective: We evaluated the influence of chronic blockade of the renin-angiotensin system on hypertension induced by long-term thyroxine (T4) administration. To this end, we determined the effects of chronic treatment with captopril on blood pressure, cardiac hypertrophy and other renal and metabolic variables of hypertensive hyperthyroid rats. Methods: T4 was administered s.c. at 0\m=.\38 \ g=m\ mol / kgper day and captopril was given in the drinking water (1\m=.\38mmol/l). Both treatments were maintained for 6 weeks. Control rats received tap water.
Introduction
Hyperthyroidism is an endocrine disease associated with important haemodynamic, renal and cardiac alter¬ ations such as increased cardiac output, reduced total peripheral resistance, increased blood pressure, a tendency to retain sodium and cardiac hypertrophy (1) (2) (3) . These characteristic cardiovascular manifesta¬ tions of hyperthyroidism are also reproduced by treatment with thyroid hormones in rats (1) (2) (3) ; these animal studies have shown a dose-and time-related increase in mean arterial pressure (MAP) (4, 5) .
The importance of the renin-angiotensin-aldosterone system (RAAS) in the long-term control of arterial pressure, renal function and cardiac hypertrophy is well established (6) (7) (8) . Hyperthyroidism is accompanied by hyperactivity of the RAAS (9) (10) (11) (12) . Thus, plasma renin activity and plasma levels of angiotensinogen. angio¬ tensin II and aldosterone are directly related to plasma levels of thyroid hormones (10) (11) (12) . Moreover, it has been shown that tri-iodothyronine (T3) treatment increases angiotensin receptor density in kidney, liver and both cardiac ventricles (12) . These Heart rate (HR) was significantly increased (P < 001 for each group) in both T4-treated groups (T4 and T4-CAP) when compared with their respective controls (C and CAP). Chronic treatment with captopril did not affect the HR in control or hyperthyroid rats (Fig. 1) .
Morphological variables
Body weight was significantly reduced in both T4-treated groups (P < 0-01 for each group) when com¬ pared with the control groups. Relative ventricular and renal weights were significantly increased in both T4-treated groups (P < 001 for each group (Table 2) .
Creatinine clearance normalized per g kidney weight was significantly reduced in the T4 group (P < 0-01). This reduction in creatinine clearance was significantly improved (P< 0-05, T4-CAP vs T4) by captopril treat¬ ment, although it did not reach the control values (P< 0-05, T4-CAP vs C). Captopril treatment did not significantly change creatinine clearance in normal rats (Table 2) .
Metabolic studies at the end of treatment showed increased food intake in both T4-treated groups (T4 = 10-81 ±0-77, T4-CAP= 9-62 ±0-47, < 001) in (Table 3) .
Discussion
In a previous study we observed that the acute administration of captopril or losartan was followed by a significant decrease in MAP in hypertensive hyper¬ thyroid rats, whereas no significant changes were observed in normal rats (13) . The (1-3) . Thus, the increased blood pressure would be mainly maintained by an increased cardiac output, which is the result of the elevated stroke volume and increased heart rate. However, the fact that hyper¬ thyroid rats treated with captopril showed normal blood pressure with increased heart rate, and probably also increased cardiac output, indicates that the increased cardiac output per se may not be the cause of hypertension in hyperthyroidism.
Hyperthyroidism resembles the clinical manifes¬ tations of a hyperadrenergic state. Despite this clinical impression, several studies have reported normal or low levels of catecholamines (14, 15) and an unaltered catecholamine responsiveness (16) . However, it has been reported that, in experimental hyperthyroidism, the heart has an increased number of /3-adrenergic receptors (17) and we also observed an increased concentration in the renal tissue (18) , which may be related to the increased renin release observed in these animals. The results of the present paper seem to indicate that the increased renal concentration of /3-adrenergic receptors plays a predominant role in the pathogenesis of T4-induced hypertension.
It is well known that the hyperthyroid state is associated with cardiac hypertrophy (2, 3, 19) . More¬ over, cardiac hypertrophy is a compensatory response secondary to the chronic increase in blood pressure, and hence usually observed in the different models of arterial hypertension (7, 8) . The results of this study show that hyperthyroidism leads to an increase in the overall ventricular size and weight, which proportion¬ ally exceed the reduction in body weight so that heartto-body weight ratio, a measure of relative ventricular hypertrophy, is increased. In addition, our results show that treatment with T4 did not influence the left-to-right ventricular weight ratio, a measure of absolute left ventricular hypertrophy. These results contrast with those reported in other models of arterial hypertension, where absolute left ventricular hypertrophy has been reported (20) . The discrepancies between these data and those found in spontaneously hypertensive rats (SHR) may be explained by the fact that hypertrophy in spontaneous hypertension is produced by increased afterload, whereas in hyperthyroidism it is secondary to hyperdynamic circulation.
One of the factors that contributes directly, or in concert with elevated blood pressure, to the develop¬ ment of cardiac hypertrophy is the renin-angiotensin system (RAS) (7, 8 (22) . The reason for these discrepancies may be the absence of absolute left ventricular hypertrophy in hypertensive hyperthyroid rats.
The metabolic study at the end of treatment showed that control and hyperthyroid rats treated with captopril had an elevated fluid intake. This effect of chronic converting enzyme inhibition on fluid intake has been reported by others (23, 24) , although the mechanism involved is not fully understood.
Contradictory findings for glomerular filtration rate (GFR) have been reported in hyperthyroid patients (1, 25, 26) and rats (27, 28 ). These differences may be due to the fact that GFR was not normalized by kidney weight, especially because hyperthyroid rats have larger kidneys than controls. Creatinine clearance in control animals was not affected by captopril, but the reduced GFR of the hyperthyroid rats was significantly improved by the converting enzyme inhibition. These results agree with our previous study showing that the acute blockade of the RAAS reversed the reduced GFR and renal blood flow in hyperthyroid hypertensive animals (13) .
In summary, this study shows that chronic treatment with captopril prevents the development of T4-induced hypertension and improves the reduced creatinine clearance of hyperthyroid rats. Therefore, these results provide evidence for the influence of the RAAS on the increased blood pressure and renal alterations present in these animals. In addition, our data demonstrate the presence of a relative ventricular hypertrophy, which was unchanged by captopril, and the absence of absolute left ventricular hypertrophy in hypertensive hyperthyroid rats.
